Clinical Trials Logo

Hepatitis B clinical trials

View clinical trials related to Hepatitis B.

Filter by:

NCT ID: NCT04847440 Terminated - Clinical trials for Hepatitis B, Chronic

A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection

Start date: March 30, 2021
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blinded, placebo-controlled, multi center, dose ranging study of safety and efficacy in both volunteers with chronic hepatitis B virus infection and in volunteers with hepatitis D virus coinfection. Volunteers will be administered multiple oral doses of ATI-2173 and assessed for safety and efficacy including blood tests to show how the body metabolizes and eliminates the investigational drug as well as how the drug effects the virus infection.

NCT ID: NCT04820686 Terminated - Chronic Hepatitis B Clinical Trials

A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection

Start date: May 7, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if vebicorvir (VBR, ABI-H0731) in combination with AB-729 is safe and effective in participants with chronic hepatitis B infection (cHBV) receiving a standard of care nucleos(t)ide/reverse transcriptase inhibitor (SOC NrtI).

NCT ID: NCT04781647 Terminated - Chronic Hepatitis B Clinical Trials

A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection

Start date: February 18, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, antiviral activity, and pharmacokinetics of ABI-H0731 in combination with entecavir (ETV) and with ETV plus pegylated-interferon alpha (Peg-IFNα) in Chinese participants with chronic hepatitis B virus infection (cHBV)

NCT ID: NCT04684914 Terminated - Clinical trials for Hepatitis B, Chronic

HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

Start date: December 26, 2020
Phase: Phase 2
Study type: Interventional

A study to evaluate the antiviral effects, immunogenicity, and safety of HepTcell in treatment-naive patients with inactive Chronic Hepatitis B (CHB) and low Hepatitis B surface antigen (HBsAg) levels.

NCT ID: NCT04485663 Terminated - Chronic Hepatitis B Clinical Trials

A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

Start date: August 17, 2020
Phase: Phase 1
Study type: Interventional

A Randomized Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

NCT ID: NCT04465916 Terminated - Clinical trials for Hepatitis B, Chronic

Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)

Start date: May 12, 2020
Phase: Phase 2
Study type: Interventional

This is a prospective, multi-centre, randomized, double-blind, placebo-controlled, Phase 2a experimental study of oral FXR modulator EYP001a/placebo combined with NAs in virologically suppressed CHB patients to improve functional cure rates.

NCT ID: NCT04454567 Terminated - Chronic Hepatitis B Clinical Trials

A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

Start date: November 11, 2020
Phase: Phase 2
Study type: Interventional

This study will explore the safety and antiviral activity of ABI-H0731 when added to a nucleos(t)ide reverse transcriptase inhibitor (NrtI) in participants who are partially virologically suppressed.

NCT ID: NCT04398134 Terminated - Chronic Hepatitis B Clinical Trials

A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection

Start date: August 28, 2020
Phase: Phase 2
Study type: Interventional

This Phase 2a study will assess the safety, antiviral activity, and pharmacokinetics (PK) of ABI-H2158 administered once daily for up to 72 weeks in combination with entecavir (ETV) in participants with chronic hepatitis B virus (HBV) infection.

NCT ID: NCT04356404 Terminated - Immunosuppression Clinical Trials

Risk of Hepatitis Flare in Patients With Previous Hepatitis B Virus Exposure Amongst Patients

Start date: May 1, 2020
Phase:
Study type: Observational

The purpose of this study is to study the risk of hepatitis flare in patients with previous hepatitis B virus exposure amongst patients on immunosuppressive and biological modifier therapies

NCT ID: NCT04059198 Terminated - Hepatitis B Clinical Trials

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus

Start date: October 10, 2019
Phase: Phase 2
Study type: Interventional

An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B treatment-naive subjects with chronic HBV infection.